8-Mercaptoquinoline, also known as 8-HQ, is a heterocyclic compound with a quinoline core and a thiol group at the 8-position. It is a white to pale yellow solid that is soluble in organic solvents. 8-HQ is an important chelating agent, forming complexes with various metal ions. It has been extensively studied for its potential applications in analytical chemistry, medicine, and materials science. 8-HQ is synthesized via the Skraup synthesis, a multi-step process involving the reaction of aniline, glycerol, and sulfuric acid. It exhibits antioxidant properties, and has been investigated as a potential treatment for various diseases. 8-HQ is used in the analysis of metals in different materials, including water, soil, and biological samples. It is also used in the production of metal-organic frameworks (MOFs) and other advanced materials. The ability of 8-HQ to form stable complexes with metal ions makes it a valuable reagent in analytical chemistry. Its diverse applications in various fields drive the ongoing research and development efforts related to this compound.'
8-mercaptoquinoline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 96028 |
| CHEMBL ID | 4076575 |
| SCHEMBL ID | 536578 |
| MeSH ID | M0232005 |
| Synonym |
|---|
| nsc-102548 |
| HMS1788G22 |
| MLS-0472512.0001 |
| nsc-48888 |
| 491-33-8 |
| nsc48888 |
| NCIOPEN2_001790 |
| quinoline-8-thiol |
| 8-mercaptoquinoline |
| AKOS024342879 |
| f77s9f93j4 , |
| 8-quinolinethiol |
| sqt-8 |
| 8-mq |
| nsc 48888 |
| unii-f77s9f93j4 |
| sodium quinolinethiolate |
| AKOS022191814 |
| MHTSJSRDFXZFHQ-UHFFFAOYSA-N |
| SCHEMBL536578 |
| F9994-0398 |
| 8tq , |
| DTXSID70197678 |
| 8-mercaptoquinoline (8tq) |
| bdbm224013 |
| FT-0735097 |
| 8-thioquinoline |
| 8-quinolinethiol;quinoline-8-thiol;8-thioquinoline |
| CHEMBL4076575 |
| 8-quinolinethiol;quinoline-8-hiol;8-thioquinoline |
| EN300-34043 |
| CS-0087175 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 26S proteasome non-ATPase regulatory subunit 14 | Homo sapiens (human) | IC50 (µMol) | 2.4500 | 0.0070 | 1.0981 | 2.5000 | AID1480589; AID1802700 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0002 | 1.1060 | 8.3000 | AID1480595 |
| 72 kDa type IV collagenase | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0000 | 1.2848 | 10.0000 | AID1480586 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0001 | 1.6847 | 9.3200 | AID1480594 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0001 | 0.5543 | 9.9000 | AID1480592 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 (µMol) | 200.0000 | 0.0000 | 0.5376 | 9.9000 | AID1480593 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1802700 | In Vitro Rpn11 Activity Assay from Article 10.1038/nchembio.2326: \\Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.\\ | 2017 | Nature chemical biology, 05, Volume: 13, Issue:5 | Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. |
| AID1480590 | Antiproliferative activity against human HCT116 cells after 72 hrs by Cell Titer-Glo assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480592 | Inhibition of full length recombinant human C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus expression system using substrate 3 preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480595 | Inhibition of human carbonic anhydrase-2 using p-nitrophenylacetate as substrate preincubated for 10 mins followed by substrate addition | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480593 | Inhibition of full length recombinant human N-terminal GST-tagged HDAC6 expressed in baculovirus expression system using substrate 3 preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480591 | Inhibition of CSN5 (unknown origin) using SCFskp2-Nedd8OG as substrate after 1 hr by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480589 | Inhibition of 26S proteasome regulatory subunit RPN11 deubiquitinating activity in human erythrocytes using Ub4-pepOG protein substrate preincubated for 1 hr followed by substrate addition measured after 80 mins by fluorescence polarization assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480594 | Inhibition of recombinant human 5-LO expressed in baculovirus infected sf9 cells using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured every minute for 20 mins by H2DCFDA dye based fluorescence assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480600 | Inhibition of BRCC36 (unknown origin) using DiUbK63TAMRA as substrate by fluorescence assay | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480586 | Inhibition of recombinant human MMP2 catalytic domain (Tyr110 to Asp452 residues) expressed in yeast using Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2.AcOH as substrate preincubated for 30 mins followed by substrate addition measured every minute for 20 mins by f | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| AID1480588 | Inhibition of 26S proteasome regulatory subunit RPN11 deubiquitinating activity in human erythrocytes at 200 uM using Ub4-pepOG protein substrate preincubated for 1 hr followed by substrate addition measured after 80 mins by fluorescence polarization assa | 2017 | Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4 | Discovery of an Inhibitor of the Proteasome Subunit Rpn11. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||